Email piyush.patel@visiongain.com for early bird discount

1. 4th Annual
Biomarkers
From characterisation and discovery, through to clinical trials and patient safety – your complete guide to biomarkers
1st - 2nd December 2011, Visiongain Conference Centre, London, UK BOOK NOW!
Key Speakers
Claudio Carini, Translational Medicine, Pfizer
Harsukh Parmar, Global Head of Early Clinical Development, Respiratory & Inflammation Therapy Area, AstraZeneca
Laura K. Richman, Vice President, MedImmune
Ge Ruigt, Director Experimental Medicine Neuroscience, Merck
Ian Hudson, Director of Licensing Division, MHRA
David Brooks, Acting Head of the Depart of Clinical Neuroscience, Imperial College London
Peter Parker, Professor of Cancer Cell Biology, King’s College, University of London
Christian Czech, Group Leader Translational Biomarkers, Roche
Theresa Zhang , Research Fellow, Merck
Parag Acharya, R&D Manager, Unilever R&D
Anna-Christine Bay-Jensen, Group Manager, Cartilage Biology and Biomarkers, Nordic Bioscience
Maarten Van Roy, Associate Scientist, Pharmacology, Ablynx
Sharmilee Gnanapavan, Neurology Specialist Registrar, Barts and the London NHS Trust
Hayley Whitaker, Research Associate, Cancer Research UK Cambridge Research Institute
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised By
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/biomarkers

2. Conference Introduction
4th Annual Biomarkers
1st - 2nd December 2011, London, UK
Dear Colleague, Media Partners:
n 2010, the global biomarkers market was an estimated value of $13.5 billion .
I 1 PharmiWeb.com is the leading industry-sponsored portal for
Forecasters predict significant growth in the years ahead with estimates of the pharmaceutical sector. Supported by most of the leading
$33.3 billion by the end of 2015. This growth will most certainly be driven pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features,
by the current demand for biomarkers in drug discovery and other areas of events listings and international jobs to industry professionals across Europe and the US.
R&D. The use of biomarkers during early stages of a product development is For further information please email: corporate@pharmiweb.com
already saving costs and time in the industry by indicating the possibility of BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
failure at an earlier stage in the research process. CROs have now recognised WORLD. It is based and located in Warsaw, Poland.
the commercial opportunities of biomarkers and are forming partnerships with
Biotechnology World was founded in 2007 to provide the world’s biotech and pharma
providers and building in-house capabilities.
information and market to make it universally accessible and useful for scientific
isiongain’s 4th Biomarkers Conference will provide attendees with an in-
V and business processes. Its first step to fulfilling that mission was building the
depth understanding of the use of biomarkers in R&D and will explore recent BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in
developments in this fast growing sector. Industry experts will also address unmet different channels. BIOTECHNOLOGY EUROPE offers companies completed internet
needs, challenges and discuss practical aspects of biomarker implementation.
public relations, publication and marketing solutions. One of the mains goals of
Why you should attend this conference BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to
global biotechnology, pharmaceutical and life science activities.
• Hear the regulatory perspective – biomarkers in drug development For further information please visit: www.biotechnology-europe.com
• Review novel targets in biomarker discovery Future Pharmaceuticals has forged powerful relationships
Driving the Industry Forward | www.futurepharmaus.com
with key industry leaders to provide a platform for successful
• Discuss how biomarkers can accelerate your clinical development
brand recognition, and for senior decision-makers to have the means to procure and
• ee how improvements in technologies are leading to better efficiency of
S plan implementation strategies based on the topics covered. Positioned to be an
biomarkers authoritative resource within top pharma companies as well as small, specialty, and
biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into
• Analyse biomarkers and their role in drug development
a highly targeted and responsive audience, bridging the gap between the industries’
• Assess preclinical safety considerations top issues and the solutions top-tier vendors can provide.
For further information please visit: www.futurepharmaus.com
• Discuss predictive biomarker discovery and development for cancer treatment
InPharm is the online platform for exclusive pharmaceutical
• Understand the role of EEG as a biomarker in psychiatry news, comment, contracts, services, jobs and events and is
• Evaluate biomarkers discovery using non-invasive metabolomics & challenges home to InPharmjobs.com, Pharmafile and Pharmafocus.
For further information please visit: www.inpharm.com
I look forward to meeting you at the conference
Best regards
Poster Presentation
At a busy conference it is hard to make sure everyone who shares your interests knows
what you are doing. Maximise your time at Visiongain’s 4th Annual Biomarkers meeting by
Koos Mohammed
sharing your results in a poster presentation. With a plethora of key decision makers, take
Conference Producer advantage of this senior networking opportunity.
Please send your 200 word abstract, in English, to: info@visiongainglobal.com for
approval. The deadline for submissions is Monday 14th November, 2011. Please include
contact details for the corresponding author(s).
Who should attend this conference? Academic institutions will not be charged a fee if booked as full-price delegates. Posters
submitted by pharmaceutical and biotechnology firms will be charged a fee of £199.
Senior VPs, Chief Scientific Officers, Directors, Managers, Professors,
Scientists, and Principal Investigators in: Posters submitted by service providers / vendors are welcome and will be subject to
• Biomarker Development Programmes evaluation. Upon approval a fee of £500 will apply. Two delegates from your organisation
• Clinical Pharmacology must be booked at full price to present a poster.
• Clinical Research Please note that all posters will be displayed at the discretion of Visiongain Ltd and are
• Drug Discovery and Development subject to approval. Due to limited space, please register your interest early.
• Recombinant DNA technology
• Medical imaging
• Safety Assessment
• Assay Development
• Proteomics/ Genomics Programmes
• Metabolomics Sponsorship and exhibition opportunities
• Epigenomics This event offers a unique opportunity to meet and do business with some of the key
• Molecular toxicology
• Regulatory Affairs players in the pharmaceutical and biotech industries. If you have a service or product
• Translational Medicine to promote, you can do so at this event by:
• Oncology
• CNS • Hosting a networking drinks reception
• Inflammation and Immunology • Taking an exhibition space at the conference
• Biological Sciences
• Diagnostics • Advertising in the delegate documentation pack
• Bioanalysis • Providing branded bags, pens, gifts, etc.
• Pharmacokinetics & Drug Metabolism
• Genomics Business Development If you would like more information on the range of sponsorship or exhibition
• Cellular & Molecular Development possibilities for visiongain's 4th Annual Biomarkers Conference, please contact us:
• Clinical Discovery Technologies
• Pharmacogenomics & Human Genetics Piyush Patel, +44 (0)20 7549 9961
• Discovery Research
• Bioengineering piyush.patel@visiongainglobal.com
Biomarkers: Technologies and Global Markets (BCC Research, March 2011)
1

3. Day 1
4th Annual Biomarkers
Thursday1st December 2011
09:00 Registration and refreshments 12:40 Networking lunch
09:30 Opening address from the Chair
Claudio Carini
13:40 Biomarker strategy for successful non-clinical to
Translational Medicine
Pfizer clinical translation
• Development of biomarker strategy
09:40 Biomarkers in drug development • Selection of species for safety and efficacy testing
CASE STUDY
– regulatory perspective • Disposition of drug-target complex as safety marker
• Regulatory acceptance of new biomarkers
• Translation of PD effect from nonclinical species to man
• Strategies for increasing the number of qualified biomarkers
Maarten Van Roy
• Challenging issues Associate Scientist, Pharmacology
Ian Hudson Ablynx
Director of Licensing Division
MHRA and CHMP Member
10:20 Precision Medicine critically affects innovation in 14:20 EEG as a biomarker in psychiatry
clinical development strategy and drug therapy Ge Ruigt
Senior Director Translational Medicine Neuroscience
• Biomarkers as part of a new paradigm
Merck
• ew study designs and re-defining the traditional pathway of
N
drug development
• eed for a more collaborative approach between basic and clinical research
N 15:00 Afternoon Refreshments
• Embracing new innovative technologies
Claudio Carini
Translational Medicine 15:20 Biomarkers target in validation and discovery in
Pfizer early development
• Strategies for accelerating development
11:00 Morning refreshments
• Reducing the risks of failures at later stages of research
Harsukh Parmar
11:20 Predictive biomarker discovery and development Global Head of Early Clinical Development, Respiratory &
for cancer treatment Inflammation Therapy Area
• iscovery of biomarkers predictive of response to oncology
D AstraZeneca
drug candidates
• evelopment of assays to assess biomarkers in human
D
tumor specimens 16:00 Selecting the right drug for patients
• Use of biomarker assays in oncology clinic trials • Demonstration of cost-effectiveness
Theresa Zhang • Adoption of tests in clinical practise
Research Fellow
Merck • Tests to reduce side effects
12:00 Biomarkers: discovery strategies and technologies
16:40 Closing remarks from the Chair
• trategies for providing truly personalised predictive biomarkers and
S
proximal biomarkers in respect of the current tranche of drugs in use
and in development
• eview of emerging new technologies for generating sophisticated
R
readouts directly informative on drug action and the prediction of
16:50 Networking drinks
drug responsiveness
Peter Parker Take your discussions further and build new
Professor of Cancer Cell Biology relationships in a relaxed and informal setting
King’s College, University of London
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011

4. Day 2
4th Annual Biomarkers
Friday 2nd December 2011
09:00 Registration and refreshments 13:40 Neurofilament heavy chain in multiple sclerosis:
from bench to bedside
• Multiple Sclerosis (MS) – what we know and the role for biomarkers
09:30 Opening address from the Chair
Hayley Whitaker • The stages of biomarker validation towards a viable surrogate end-point
Research Associate • eurodegeneration and evaluation of axonal pathology using
N
Cancer Research UK Cambridge Research Institute neurofilament heavy chain
• eurofilaments in clinical trial: cannabiniods in CREAE and Lamotrigine in
N
09:40 Rational biomarker strategies in drug development Secondary Progressive MS
• Use of biomarkers in early stages of drug development • The future: BioMS-eu consortium for biomarker research
Sharmilee Gnanapavan
• Maximising utility of pharmacodynamic markers in drug development
Neurology Specialist Registrar
• Examples of biomarker strategies in drug development Barts and the London NHS Trust
Laura K. Richman
Vice President
MedImmune 14:20 The role of molecular imaging for drug
development in CNS disorders
• MI can:
10:20 Biochemical markers of ongoing joint damage
in arthritis - current and future biomarkers of - Support clinical diagnosis and aid screening for trials
prognosis and efficacy measurements - Follow disease progression
• Targeting pathology specific markers - Help understand disease mechanisms
• xamples of novel biochemical markers of extracellular matrix
E - Help understand drug mechanisms
remodelling, Neo-Epitopes
- llow dose-receptor / enzyme occupancy profiles to be generated for
A
• se of a pathological relevant biochemical markers for prognosis and
U novel therapeutics
treatment efficacy in rheumatoid and joint degenerative diseases
David Brooks
Anna-Christine Bay-Jensen Acting Head of the Depart of Clinical Neuroscience
Group Manager, Cartilage Biology and Biomarkers Imperial College London
Nordic Bioscience
15:00 Afternoon refreshments
11:00 Morning refreshments
15:20 Biomarkers for CNS diseases: Of Mice and Men
11:20 Biomarkers discovery using non-invasive
metabolomics & challenges • Challenge of Identifying CNS biomarkers
• Metabolomics - what’s new? • Technologies for biomarker identification and their application
• Non-invasive metabolomics - why, where & how • Examples for new CNS biomarkers and how they have been identified
• etabolomics based biomarker discovery - current status, emerging scope
M Christian Czech
& future challenges Group Leader Translational Biomarkers
Roche
Parag Acharya
R&D Manager
Unilever R&D 16:00 Biomarker data management and analysis
• ew technologies around biomarkers and their interplay with
N
12:00 Sponsor Spotlight Session drug development
T
ake this unique opportunity to be a part of the conference • Minimising risks: emerging technologies and their implications
theme, network, share ideas and provide an overview of your
product/services to the audience. For more information please contact
piyush.patel@visiongainglobal.com 16:40 Chair’s closing remarks
12:40 Networking lunch 16:50 End of Conference

5. Registration Form
4th Annual Biomarkers
1st - 2nd December 2011, London, UK
Angel
Conf. code PP Pentonville Road
4th Annual Biomarkers
Ci
Standard Prices
ty
Ro
ad
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80
1st - 2nd December 2011
Old Street
Location: Visiongain Conference Centre
Number of bookings: Total cost:
Old Street
Address:
230 City Road
London
Promotional Literature Distribution
City Road
EC1V 2TT
Distribution of your company’s promotional literature to all conference attendees UK
Fee: £999 VAT: £199.80 Total: £1198.80
Details How to book
Forename: Surname: Email: piyush.patel@visiongain.com
Web: http://www.visiongain.com/biomarkers
Job Title: Company: UK Office:
Tel: +44(0) 20 7549 9961
Fax: +44(0) 20 7549 9932
Main Switchboard Number:
Visiongain Ltd
BSG House
Address: 226-236 City Road
London
EC1V 2QY
UK
Country: Postcode: General information
Venue: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United Kingdom. Closest tube
Phone: Fax: station is Old Street (Northern Line).
Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376
9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343
Email: http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.html
Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207
Signature: 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
I confirm that I have read and agree to the terms and conditions of booking Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
right to charge interest on unpaid invoices.
Methods of payment
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Payment must be made in sterling made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
after one month before the start of the event. Should you decide to cancel after this date, the full invoice
By Mail: Complete and return your signed registration form together with your cheque payable must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK between conferences. However, if you cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email, fax or post. Name changes and
By Fax: Complete and fax your signed registration form with your credit card details substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
to +44 (0) 20 7549 9932
Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932
Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
By Bank Transfer: briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
Visiongain Ltd A/C: visiongain Ltd to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
expenses, which may be incurred by the customer as a consequence of the event being postponed or
Barclays Bank Sort Code: 20-71-64
cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
Piccadilly Branch Account No: 6038 7118 cost of the registration, travel and expenses.
48 Regent Street Swift Code: BARC GB22
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
London, W1B 5RA IBAN: GB80 BARC 20716460387118 Protection Act 1988. Your personal information contained in this form may be used to update you on
visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
Please debit my credit card: may also share your data with external companies offering complementary products or services. If you
wish for your details to be amended, suppressed or not passed on to any external third party, please
Access MasterCard Visa American Express send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
Card number: visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
Expiry Date: recommend you obtain).
VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
Security number (last 3 digits on back of credit card): incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Signature: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Cardholder’s name: Unable to attend
Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
News updates with your payment. You will receive speaker talks in PDFs two weeks after the event.
Please tick if you do not want to receive email news updates in the future Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
www.visiongain.com/biomarkers